Phase II Trial to Compare the Safety of Two Chemotherapy Plus Trastuzumab Regimens as Adjuvant Therapy for HER2-positive Breast Cancer (Study P05048)

NCT00550771 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

181

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasm

Interventions

DRUG: doxorubicin, cyclophosphamide, paclitaxel, trastuzumab
DRUG: PLD, cyclophosphamide, trastuzumab, paclitaxel

Sponsor

Merck Sharp & Dohme LLC